Accumulus Synergy’s Post

Great experience little time ago to share “’Smart Sampling': Innovations in Patient-Centric Sampling” at the Clinical Trials Innovation Summit 2023, organized by PanAgora Pharma and Roche. The thread was to show that Patient-Centric Sampling enables (more of) blood sampling the “AAAA-way” – Anyone (lower blood volumes, painless sampling for vulnerable populations; but not limited to!), Anywhere (at home, remote locations), Anytime (event-driven sampling), and by Anyone (self-sampling). Maybe not all the 4 As at the same time first, but let’s start with a subset! This is reality, as shown by publications for each of these use cases! Patient-centricity – or human-centricity, as discussed by many presenters during these 2 days, as patients are first humans, and clinical trials involve many different people – should be at the heart of what we do. Patient advocates reminded us of this in a vibrant and touching ways. Thank you! (pictures: Sam Hariry and Jacek Lukawy) #ClinicalTrialsInnovationSummit #PanAgoraPharma #Roche #bloodsampling #microsampling #patientcentricsampling #humancentricity #clinicaltrials #innovation

Glad to see NPC & Tufts discuss dynamic pricing. We need more people talking about this. We published research on this in JMCP in 2020 demonstrating a need for “continuous CEA” using the Hepatitis C market as a case study to show how dynamic markets make single Value Assessments obsolete pretty quickly. #drugpricing #value https://lnkd.in/gzMpii-3

How can real-world evidence (RWE) transform healthcare and clinical trials? Imagine a world where patients effortlessly access their medical records and actively engage in research. Whyze Health is at the forefront of this revolution. Our platform connects all stakeholders, from patients to pharma, using robust RWE to streamline clinical trials and improve decision-making. RWE boosts patient outcomes and promises to transform Ireland's clinical research landscape. Learn how Whyze Health is reshaping the future of healthcare in this enlightening article: https://lnkd.in/eAP2zqVA

Efortless.bio Today! 1. MorphoSys's phase 3 trial of CPI-0610 shows positive results in treating Myelofibrosis MorphoSys today announced topline results of the phase 3 study of CPI-0610(Pelabresib) for the treatment of Myelofibrosis (MF) https://lnkd.in/gVT7_GYu 2. Plus Therapeutics' phase 2 trial of rhenium(186Re) obisbemeda shows longer median overall survival in glioblastoma patients Plus Therapeutics today announced interim results of the phase 2 study of rhenium(186Re) obisbemeda, a radioconjugate, in patients with glioblastoma(rGBM). The study showed a median overall survival(mOS) of 13 months in a group of 15 patients, which was 63% longer than the current standard of care. https://lnkd.in/gS22AGTq 3. Agios Pharmaceuticals's phase 2a trial in LR-MDS demonstrates positive results for anemia treatment Agios Pharmaceuticals today announced interim results of the phase 2a study of AG-946, a potential treatment for anemia in lower-risk myelodysplastic syndromes(LR-MDS). The primary endpoints, including transfusion independence and hemoglobin response, showed promising results in a subset of patients. https://lnkd.in/g7rkU5zX If you would like a free market report on an indication you are interested in, please let me know in any way and I will provide it within 24 hours.

📚 Check out this insightful article on Achieving Market Access Excellence with a Strategic Integrated Evidence Generation Plan! Discover how evidence generation can enhance market access and improve patient outcomes.🔍 Don't miss it: @capsysgroup

Deal Cansino biologics partners with SPIMACO to bring menhycia vaccine for meningococcal disease to saudi arabia and key mena markets ➡ https://lnkd.in/gCWSX9PB Saniona and boehringer ingelheim amend ongoing collaboration, for CNS ion channel target drug candidates in schizophrenia treatment, with research funding ➡https://lnkd.in/g7pyNa6f Genequantum healthcare partners with biomap in strategic collaboration for development of novel ADC candidate, utilizing proprietary conjugation technology platforms ➡https://lnkd.in/gadXPbhQ Clinical Trials Sensorion's phase 2a trial of SENS-401 shows preliminary safety data in hearing disorders induced by cisplatin ➡ https://lnkd.in/ggJJJTaa Invivyd's phase 3 trial of INVYMAB shows high serum virus neutralizing antibody titer levels in immunocompromised participants for prevention of symptomatic COVID-19 ➡ https://lnkd.in/grFZ-XFV

This morning, I had the privilege of listening to @Siân Ratcliffe from Biogen share her invaluable insights from the clinical operations leadership perspective. The challenges she addressed are very much at the forefront of our post-pandemic industry landscape. Here are my top takeaways: It's essential to assess the practices we adopted out of necessity during the pandemic and refine them for repeatability, scalability, and flawless execution. As the pandemic's strain on our systems continues, we need to ensure that our research ecosystem doesn't overburden trial sites or participants. It’s heartening to see trial sponsors making concerted efforts to lighten the load for sites and participants through optimized study designs, better resourcing, and innovating with new trial models. The challenges of lower patient participation, site staffing, escalating expenses, and complex trial designs cannot be understated. With findings showing 40% of respondents feel investigator grants don't adequately fund expenses, it's evident that more funding is crucial for site sustainability or I would add, significantly enhanced efficiency which can help make sites a site of choice. While decentralization brings benefits, it also introduces new challenges. Ensuring that our approach remains centered around sites and patients is paramount. That said, the future is promising! With an evolving research ecosystem, protocol flexibility, a focus on bringing the study to the patient, and patient-centered decentralization, we're on a path to more inclusive, efficient, and patient-centric trials. #DPharm2023 #ClinicalTrials #PatientCentricity #LegacyHealthStrategies

Türkiye is becoming an attractive destination for clinical trials due to its robust healthcare infrastructure and a large pool of treatment-naive patients. In our latest video interview, CEO of Cromos Pharma, Vlad Bogin, MD, FACP, speaks with Seniz Sagol Tuysuz, the Country Head of Cromos Pharma in Türkiye. They explore why Türkiye is emerging as a biotech hub, discussing the clinical trial landscape, regulatory environment, quality and safety measures, patient recruitment, and best practices for successful trials. Discover why Türkiye should be considered for the next clinical research venture: https://lnkd.in/e6EgU7Gb #Podcast #Türkiye #CromosPharma

This excellent editorial by Marc Buyse deftly illuminates the promise and the progress made in sharing health data, but also shows how far we have to go. Summarizing the ideal state, Dr. Buyse concludes: "Patients consent to the trial procedures with the implicit understanding that their data will be used to further medical knowledge, and indeed, in an ideal world, the cumulative data from all randomized clinical trials would be a treasure trove for clinical researchers... Evidence-based medicine would cease to be a long-term objective for most indications. We owe it to patients who accept participation in randomized clinical trials to get as close as possible to this ideal." Grateful for many colleagues and companies working toward this ideal via different strategies/models, including Rebecca Li at Vivli, Christine Lemke at Evidation, and Terry Myerson at Truveta #clinicaltrials #datasharing #learninghealthsystem #precisionmedicine #evidencebasedmedicine #datasharingisdatacaring

Türkiye is becoming an attractive destination for clinical trials due to its robust healthcare infrastructure and a large pool of treatment-naive patients. In our latest video interview, CEO of Cromos Pharma, Vlad Bogin, MD, FACP, speaks with Seniz Sagol Tuysuz, the Country Head of Cromos Pharma in Türkiye. They explore why Türkiye is emerging as a biotech hub, discussing the clinical trial landscape, regulatory environment, quality and safety measures, patient recruitment, and best practices for successful trials. Discover why Türkiye should be considered for the next clinical research venture: https://lnkd.in/edcWNWyk #Podcast #Türkiye #CromosPharma